Pr Francois DUCRAY
Neuro-oncology department
The neuro-oncology department is interested in the management of brain tumors and the neurological complications of systemic cancers. It is also the National Reference Center for paraneoplastic neurological syndromes and autoimmune encephalitis.
Research themes
Full professor of neurology, president of the ANOCEF, François Ducray’s clinical activity is dedicated to brain tumor patients. He leads several national and international (EORTC) clinical trials and a research group at the Cancer Research Center of Lyon. His research activity is focused on multi-omic characterization of adult gliomas (glioblastomas, IDH-mutated gliomas) and development of new pre-clinical models of gliomas in close collaboration with the French POLA network.
Main ongoing projects
- Proteomic Characterization of Aggressive Oligodendrogliomas (PROGLIO) NCT04843085
- A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery (POLO) NCT04702581
Publications
1. Figarella-Branger D, Colin C, Mokhtari K, et al. Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort. Neuro-Oncol. 2025;27(3):755-766. doi:10.1093/neuonc/noae221
2. Kacimi SEO, Dehais C, Feuvret L, et al. Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. J Clin Oncol Off J Am Soc Clin Oncol. 2025;43(3):329-338. doi:10.1200/JCO.24.00049
3. Esparragosa Vazquez I, Sanson M, Chinot OL, et al. Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network. Neuro-Oncol Adv. 2024;6(1):vdae078. doi:10.1093/noajnl/vdae078
4. Picca A, Touat M, Belin L, et al. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. Eur J Cancer Oxf Engl 1990. 2024;202:114034. doi:10.1016/j.ejca.2024.114034
5. Ducray F, Ramirez C, Robert M, et al. A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules. Pharmaceutics. 2023;15(12):2664. doi:10.3390/pharmaceutics15122664
